Carbapenem-based Antibiotics Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2019 to 2029

Published on : Dec-2019 | List of Tables : 42 | List of Figures : 110 | No. of Pages : 170 | Report Code : FACT4425MR | Format :

Carbapenem-based Antibiotics Market to Register Strong Growth, on Back of Increasing Incidence of Hospital Acquired Pneumonia and Bacterial Infections

Incidence of bacterial infections is increasing rapidly across the world offering significant revenue generating opportunities for the carbapenem-based antibiotics market. Pneumonia acquired in hospital settings due to longer patient stays, is often difficult to treat and exists as the comorbidity to various chronic diseases such as cancer, organ transplant. etc. It also interferes with the disease treatment and may be fatal if not treated with broad-spectrum antibiotics such as carbapenem-based antibiotics.

As per the Center for Disease Control (CDC), people admitted to hospital settings due to various reasons such as immunosuppressive treatment and inappropriately followed infection control protocol, suffer from hospital-acquired pneumonia (HAP). Along with HAP, incidence of various bacterial diseases is increasing rapidly, which in turn is expected to drive the growth of the carbapenem-based antibiotics market.

carbapenem based antibiotics market

To get an incisive view of the carbapenem-based antibiotics market, ask an analyst here

Surgery-Associated Bacterial Infection to Boost Demand for Carbapenem-Based Antibiotics

Some forms of chronic diseases often require open surgery as a treatment protocol. Before performing open surgery, carbapenem-based antibiotics are often administered as the prophylactic measure for the prevention of surgery-related bacterial infections. The World Health Organization also emphasizes on infection control protocol i.e. prophylactic administration of the carbapenem-based antibiotics that can limit or eliminate the chances of surgery-associated bacterial infection. As per WHO, 30% of global disease burden is accruing to surgery related diseases pointing towards a heightened demand for prophylactic, carbapenem-based antibiotics.

Carbapenem-based Antibiotics Market Gains Traction, with Generic Alternatives to Ertapenem to be Lucrative Revenue Pockets

Ertapenem is one of the most widely used carbapenem-based antibiotics and its patent expired in November 2017. Various regional as well as global pharmaceutical companies are assessing feasibility for possible re- launch of generic version of ertapenem in various regions. For instance, in June 2018, Aurobindo Pharma received FDA approval for generic Invanz injection. Invanz is Merck Sharp and Dohme Corp.’s joint carbapenem-based antibiotic product for the treatment of various bacterial infections.  The launch of various generic version of carbapenem-based antibiotics such as ertapenem in regions such as North America and Europe is expected to offer substantial revenue generation opportunities. Lower price of generic carbapenem-based antibiotics is expected to result in increased product adoption, thus compelling carbapenem-based antibiotic manufacturers to enhance geographical footprint in lower- and middle-income countries. Increasing supply-chain operations in regions such as North America, East Asia and Europe will further give impetus to high revenue generating carbapenem-based antibiotics markets.

carbapenem based antibiotics market 01

To get strategic and exhaustive insights on the carbapenem-based antibiotics market, request for a report sample here

Competitive Landscape

Pfizer Inc., Merck Co. & Inc. and Sumitomo Dainippon Pharma Co., Ltd. are top players operating in the carbapenem-based antibiotics market. The top three players contributed more than 92% revenue share in the carbapenem-based antibiotics market in 2018. Key players are prominently focusing on increasing their carbapenem-based antibiotics availability in different countries for the treatment of a large patient pool with bacterial infections.

Carbapenem-based Antibiotics Market - Scope of Report

Fact.MR recently published a market study on the global market for carbapenem-based antibiotics. The study provides detailed assessment on the key market dynamics, including drivers, trends, opportunities restraints, and detailed information about the carbapenem-based antibiotics market structure. The market study presents exclusive information about how the carbapenem-based antibiotics market will grow during the forecast period 2019-2029.

Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market, and compounded annual growth rate (CAGR) are explained in Fact.MR’s study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of the carbapenem-based antibiotics market during the forecast period.

The study is relevant for stakeholders in the carbapenem-based antibiotics market, including carbapenem-based antibiotics products manufactures, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in the carbapenem-based antibiotics market, investors, industry experts, researchers, and journalists, as well as business researchers can leverage the information and data presented in Fact.MR’s study.

The study also includes statistics as well as facts related to macroeconomic factors that are impacting developments in the market. It also offers actionable insights based on the future trends in the carbapenem-based antibiotics market. Furthermore, small businesses and new entrants in the carbapenem-based antibiotics market too can make use of the information presented in this study, based on, which they can make appropriate business decisions to gain momentum in the carbapenem-based antibiotics market.

Key Segments of Carbapenem-based Antibiotics Market

Fact.MR’s study on the carbapenem-based antibiotics therapy market offers information divided into four important segments - product, indication, sales channel, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.

Product Type

Indication

Sales Channel

Region

  • Meropenem
  • Ertapenem
  • Imipenem
  • Doripenem
  • Panipenem
  • Tebipenem
  • Intra-abdominal Infections
  • Urinary Tract Infections
  • Pneumonia
  • Bacterial Meningitis
  • Skin and Skin Structure Infections
  • Acute Pelvic Infections
  • Prophylaxis of Surgical Site Infection
  • Respiratory Tract Infections
  • Gynaecologic Infections
  • Endocarditis
  • Others
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Key Questions Answered in Fact.MR’s Carbapenem-based Antibiotics Market Report

  • Which regions will continue to remain the most profitable regional markets for carbapenem-based antibiotics market players?
  • Which factors will essentially induce a change in the demand for carbapenem-based antibiotics in the forecast period?
  • How will changing trends impact the carbapenem-based antibiotics market?
  • What are key manufacturers’ strategy to enhance their product adoption and improve regional product footprints?
  • Which companies are leading the carbapenem-based antibiotics market?
  • What are the winning strategies of stakeholders in the carbapenem-based antibiotics market to upscale their position in this landscape?

Carbapenem-based Antibiotics Market: Research Methodology

In Fact.MR’s study, a unique research methodology is utilized to conduct extensive research on the growth of the carbapenem-based antibiotics market, and reach conclusions on future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure accuracy and reliability of conclusions.

Secondary resources referred to analysts during the production of the carbapenem-based antibiotics market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies in the carbapenem-based antibiotics market, and makes Fact.MR’s projection on the growth prospects of the carbapenem-based antibiotics market more accurate and reliable.

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Product Innovation / Development Trends

    3.3. Technology Roadmap

4. Key Success Factors

    4.1. New Product Launches and Approvals

    4.2. Consumption of Carbapenem-based Antibiotics

    4.3. Promotional and Marketing Strategies

5. Global Carbapenem-based Antibiotics Market Demand (in Value or Size in US$ Mn) Analysis 2014-2018 and Forecast, 2019-2029

    5.1. Historical Market Value (US$ Mn) Analysis, 2014-2018

    5.2. Current and Future Market Value (US$ Mn) Projections, 2019-2029

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

6. Market Background

    6.1. Macro-Economic Factors

    6.2. Forecast Factors - Relevance & Impact

    6.3. Regulatory Scenario

    6.4. Market Dynamics

        6.4.1. Drivers

        6.4.2. Restraints

        6.4.3. Opportunity Analysis

7. Global Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029, by Product Type 

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2014 - 2018

    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product Type, 2019 - 2029

        7.3.1. Meropenem 

        7.3.2. Ertapenem 

        7.3.3. Imipenem 

        7.3.4. Doripenem 

        7.3.5. Panipenem

        7.3.6. Tebipenem

    7.4.  Market Attractiveness Analysis By Product Type

8. Global Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029, by Indication 

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2014 - 2018

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2019 - 2029

        8.3.1. Intra-abdominal Infections

        8.3.2. Urinary Tract Infections

        8.3.3. Pneumonia

        8.3.4. Bacterial Meningitis

        8.3.5. Skin and Skin Structure Infections

        8.3.6. Acute Pelvic Infections

        8.3.7. Prophylaxis of Surgical Site Infection

        8.3.8. Respiratory Tract Infections

        8.3.9. Gynaecologic Infections

        8.3.10. Endocarditis

        8.3.11. Others 

    8.4.  Market Attractiveness Analysis By Indication

9. Global Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029, by Sales Channel

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Sales Channel, 2014 - 2018

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Sales Channel, 2019 - 2029

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies & Drug Stores

        9.3.3. Online Pharmacies

    9.4. Market Attractiveness Analysis By Sales Channel

10. Global Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029, by Region

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) and Volume Analysis By Region, 2014 - 2018

    10.3. Current Market Size (US$ Mn) and Volume Analysis and Forecast By Region, 2019 - 2029

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. East Asia

        10.3.5. South Asia

        10.3.6. Oceania

        10.3.7. Middle East and Africa (MEA)

    10.4. Market Attractiveness Analysis By Region

11. North America Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014 - 2018

    11.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2019 - 2029

        11.3.1.  By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Product Type

        11.3.3. By Indication

        11.3.4. By Sales Channel

    11.4. Market Attractiveness Analysis

        11.4.1. By Country

        11.4.2. By Product Type

        11.4.3. By Indication

        11.4.4. By Sales Channel

    11.5. Drivers and Restraints - Impact Analysis

12. Latin America Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014 - 2018

    12.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2019 - 2029

        12.3.1.  By Country

            12.3.1.1. Brazil

            12.3.1.2. Mexico

            12.3.1.3. Rest of Latin America

        12.3.2. By Product Type

        12.3.3. By Indication

        12.3.4. By Sales Channel

    12.4. Market Attractiveness Analysis

        12.4.1. By Country

        12.4.2. By Product Type

        12.4.3. By Indication

        12.4.4. By Sales Channel

    12.5. Drivers and Restraints - Impact Analysis

13. Europe Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014 - 2018

    13.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2019 - 2029

        13.3.1. By Country

            13.3.1.1. Germany

            13.3.1.2. Italy

            13.3.1.3. France

            13.3.1.4. U.K.

            13.3.1.5. Spain

            13.3.1.6. BENELUX

            13.3.1.7. Russia

            13.3.1.8. Rest of Europe

        13.3.2. By Product Type

        13.3.3. By Indication

        13.3.4. By Sales Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Product Type

        13.4.3. By Indication

        13.4.4. By Sales Channel

    13.5. Drivers and Restraints - Impact Analysis

14. South Asia Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014 - 2018

    14.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2019 - 2029

        14.3.1. By Country

            14.3.1.1. India

            14.3.1.2. Thailand

            14.3.1.3. Indonesia

            14.3.1.4. Malaysia

            14.3.1.5. Rest of South Asia

        14.3.2. By Product Type

        14.3.3. By Indication

        14.3.4. By Sales Channel

    14.4. Market Attractiveness Analysis

        14.4.1. By Country

        14.4.2. By Product Type

        14.4.3. By Indication

        14.4.4. By Sales Channel

    14.5. Drivers and Restraints - Impact Analysis

15. East Asia Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014 - 2018

    15.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2019 - 2029

        15.3.1.  By Country

            15.3.1.1. China

            15.3.1.2. Japan

            15.3.1.3. South Korea

        15.3.2. By Product Type

        15.3.3. By Indication

        15.3.4. By Sales Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Product Type

        15.4.3. By Indication

        15.4.4. By Sales Channel

    15.5. Drivers and Restraints - Impact Analysis

16. Oceania Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market Taxonomy, 2014 - 2018

    16.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2019 - 2029

        16.3.1.  By Country

            16.3.1.1. Australia

            16.3.1.2. New Zealand

        16.3.2. By Product Type

        16.3.3. By Indication

        16.3.4. By Sales Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Product Type

        16.4.3. By Indication

        16.4.4. By Sales Channel

    16.5. Drivers and Restraints - Impact Analysis

17. Middle East and Africa Carbapenem-based Antibiotics Market Analysis 2014-2018 and Forecast 2019-2029

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) and Volume Trend Analysis By Market   Taxonomy, 2014 - 2018

    17.3. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2019 - 2029

        17.3.1.  By Country

            17.3.1.1. GCC Countries

            17.3.1.2. Turkey

            17.3.1.3. Northern Africa

            17.3.1.4. South Africa

            17.3.1.5. Rest of Middle East and Africa

        17.3.2. By Product Type

        17.3.3. By Indication

        17.3.4. By Sales Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Product Type

        17.4.3. By Indication

        17.4.4. By Sales Channel

    17.5. Drivers and Restraints - Impact Analysis

18. Market Structure Analysis

    18.1. Market Analysis by Tier of Companies

    18.2. Market Share Analysis of Top Players, by Region

    18.3. Market Presence Analysis

        18.3.1. By Regional footprint of Players

        18.3.2. Product foot print by Players

        18.3.3. Channel Foot Print by Players

19. Competition Analysis

    19.1. Competition Dashboard

    19.2. Competition Benchmarking

    19.3. Competition Deep Dive (Tentative List)

        19.3.1. ACS Dobfar S.p.A. 

            19.3.1.1. Overview

            19.3.1.2. Product Portfolio

            19.3.1.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.1.4. Sales Footprint

            19.3.1.5. Strategy Overview

                19.3.1.5.1. Marketing Strategy

                19.3.1.5.2. Product Strategy

                19.3.1.5.3. Channel Strategy

        19.3.2. Amneal Pharmaceuticals LLC

            19.3.2.1. Overview

            19.3.2.2. Product Portfolio

            19.3.2.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.2.4. Sales Footprint

            19.3.2.5. Strategy Overview

                19.3.2.5.1. Marketing Strategy

                19.3.2.5.2. Product Strategy

                19.3.2.5.3. Channel Strategy

        19.3.3. Apotex, Inc.

            19.3.3.1. Overview

            19.3.3.2. Product Portfolio

            19.3.3.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.3.4. Sales Footprint

            19.3.3.5. Strategy Overview

                19.3.3.5.1. Marketing Strategy

                19.3.3.5.2. Product Strategy

                19.3.3.5.3. Channel Strategy

        19.3.4. Aurobindo Pharma Ltd.

            19.3.4.1. Overview

            19.3.4.2. Product Portfolio

            19.3.4.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.4.4. Sales Footprint

            19.3.4.5. Strategy Overview

                19.3.4.5.1. Marketing Strategy

                19.3.4.5.2. Product Strategy

                19.3.4.5.3. Channel Strategy

        19.3.5. Daewoong Pharmaceutical Co., Ltd.

            19.3.5.1. Overview

            19.3.5.2. Product Portfolio

            19.3.5.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.5.4. Sales Footprint

            19.3.5.5. Strategy Overview

                19.3.5.5.1. Marketing Strategy

                19.3.5.5.2. Product Strategy

                19.3.5.5.3. Channel Strategy

        19.3.6. Fedora Pharmaceuticals, Inc.

            19.3.6.1. Overview

            19.3.6.2. Product Portfolio

            19.3.6.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.6.4. Sales Footprint

            19.3.6.5. Strategy Overview

                19.3.6.5.1. Marketing Strategy

                19.3.6.5.2. Product Strategy

                19.3.6.5.3. Channel Strategy

        19.3.7. Gland Pharma Ltd. (Fosun Pharmaceutical Co., Ltd.)

            19.3.7.1. Overview

            19.3.7.2. Product Portfolio

            19.3.7.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.7.4. Sales Footprint

            19.3.7.5. Strategy Overview

                19.3.7.5.1. Marketing Strategy

                19.3.7.5.2. Product Strategy

                19.3.7.5.3. Channel Strategy

        19.3.8. Iterum Therapeutics plc

            19.3.8.1. Overview

            19.3.8.2. Product Portfolio

            19.3.8.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.8.4. Sales Footprint

            19.3.8.5. Strategy Overview

                19.3.8.5.1. Marketing Strategy

                19.3.8.5.2. Product Strategy

                19.3.8.5.3. Channel Strategy

        19.3.9. Jeil Pharmaceutical Co., Ltd.

            19.3.9.1. Overview

            19.3.9.2. Product Portfolio

            19.3.9.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.9.4. Sales Footprint

            19.3.9.5. Strategy Overview

                19.3.9.5.1. Marketing Strategy

                19.3.9.5.2. Product Strategy

                19.3.9.5.3. Channel Strategy

        19.3.10. Johnson & Johnson Pharmaceuticals

            19.3.10.1. Overview

            19.3.10.2. Product Portfolio

            19.3.10.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.10.4. Sales Footprint

            19.3.10.5. Strategy Overview

                19.3.10.5.1. Marketing Strategy

                19.3.10.5.2. Product Strategy

                19.3.10.5.3. Channel Strategy

        19.3.11. Meiji Seika Pharma Co., Ltd.

            19.3.11.1. Overview

            19.3.11.2. Product Portfolio

            19.3.11.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.11.4. Sales Footprint

            19.3.11.5. Strategy Overview

                19.3.11.5.1. Marketing Strategy

                19.3.11.5.2. Product Strategy

                19.3.11.5.3. Channel Strategy

        19.3.12. Merck & Co., Inc.

            19.3.12.1. Overview

            19.3.12.2. Product Portfolio

            19.3.12.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.12.4. Sales Footprint

            19.3.12.5. Strategy Overview

                19.3.12.5.1. Marketing Strategy

                19.3.12.5.2. Product Strategy

                19.3.12.5.3. Channel Strategy

        19.3.13. Pfizer, Inc.

            19.3.13.1. Overview

            19.3.13.2. Product Portfolio

            19.3.13.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.13.4. Sales Footprint

            19.3.13.5. Strategy Overview

                19.3.13.5.1. Marketing Strategy

                19.3.13.5.2. Product Strategy

                19.3.13.5.3. Channel Strategy

        19.3.14. Savior Lifetec Corporation

            19.3.14.1. Overview

            19.3.14.2. Product Portfolio

            19.3.14.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.14.4. Sales Footprint

            19.3.14.5. Strategy Overview

                19.3.14.5.1. Marketing Strategy

                19.3.14.5.2. Product Strategy

                19.3.14.5.3. Channel Strategy

        19.3.15. Spero Therapeutics, Inc.

            19.3.15.1. Overview

            19.3.15.2. Product Portfolio

            19.3.15.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.15.4. Sales Footprint

            19.3.15.5. Strategy Overview

                19.3.15.5.1. Marketing Strategy

                19.3.15.5.2. Product Strategy

                19.3.15.5.3. Channel Strategy

        19.3.16. Sumitomo Dainippon Pharma Co., Ltd. 

            19.3.16.1. Overview

            19.3.16.2. Product Portfolio

            19.3.16.3. Profitability by Market Segments (Product/Channel/Region)

            19.3.16.4. Sales Footprint

            19.3.16.5. Strategy Overview

                19.3.16.5.1. Marketing Strategy

                19.3.16.5.2. Product Strategy

                19.3.16.5.3. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Carbapenem-based Antibiotics Market Forecast, Trend Analysis & Competition Tracking - Global Market Insights 2019 to 2029